Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

News

Conference Coverage
12/10/2022

Craig Ostroff

Craig Ostroff
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues...
12/10/2022
Journal of Clinical Pathways
News
11/17/2022

Gina Tomaine

Gina Tomaine
Momelotinib improved symptom responses, transfusion requirements, and spleen responses for symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor when compared with danazol, according to the phase 3 MOMENTUM...
Momelotinib improved symptom responses, transfusion requirements, and spleen responses for symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor when compared with danazol, according to the phase 3 MOMENTUM...
Momelotinib improved symptom...
11/17/2022
Oncology
News
10/25/2022

Yvette C Terrie

Yvette C Terrie
Renal cell carcinoma (RCC) recurrence is correlated with a significant increase in mortality, health care resource utilization (HRU), and health care costs, emphasizing the substantial unmet need in patients with intermediate high-risk and...
Renal cell carcinoma (RCC) recurrence is correlated with a significant increase in mortality, health care resource utilization (HRU), and health care costs, emphasizing the substantial unmet need in patients with intermediate high-risk and...
Renal cell carcinoma (RCC)...
10/25/2022
Journal of Clinical Pathways
News
10/18/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recently published study reveal that participation in the Oncology Care Model (OCM) did not dissuade oncologists from prescribing expensive, novel therapies to Medicare beneficiaries with cancer.
Findings from a recently published study reveal that participation in the Oncology Care Model (OCM) did not dissuade oncologists from prescribing expensive, novel therapies to Medicare beneficiaries with cancer.
Findings from a recently...
10/18/2022
Journal of Clinical Pathways
News
10/18/2022
Momelotinib was superior to danazol in symptomatic, anemic, and thrombocytopenic myelofibrosis patients for symptom responses, transfusion requirements, and spleen responses, according to a phase 3 trial.
Momelotinib was superior to danazol in symptomatic, anemic, and thrombocytopenic myelofibrosis patients for symptom responses, transfusion requirements, and spleen responses, according to a phase 3 trial.
Momelotinib was superior to...
10/18/2022
Oncology
News
10/07/2022

Yvette C Terrie

Yvette C Terrie
A recent study found that second-line chemotherapy among patients with NSCLC complicated by interstitial lung disease (ILD) has a certain effectiveness, but some patients may experience harsh adverse effects of ILD.
A recent study found that second-line chemotherapy among patients with NSCLC complicated by interstitial lung disease (ILD) has a certain effectiveness, but some patients may experience harsh adverse effects of ILD.
A recent study found that...
10/07/2022
Journal of Clinical Pathways
News
10/06/2022

Yvette C Terrie

Yvette C Terrie
Immunoglobulin G (IgG) class-switched mutated chronic lymphocytic leukemia (M-CLL) likely represents the same disease as IgM M-CLL rather than a different biological and/or clinical entity, according to a recent study.
Immunoglobulin G (IgG) class-switched mutated chronic lymphocytic leukemia (M-CLL) likely represents the same disease as IgM M-CLL rather than a different biological and/or clinical entity, according to a recent study.
Immunoglobulin G (IgG)...
10/06/2022
Journal of Clinical Pathways
News
10/06/2022

Yvette C Terrie

Yvette C Terrie
The uptake of targeted oral anticancer medicines expanded from 3.6% to 8.9% in a study population between 2011 to 2016, according to a recent study.
The uptake of targeted oral anticancer medicines expanded from 3.6% to 8.9% in a study population between 2011 to 2016, according to a recent study.
The uptake of targeted oral...
10/06/2022
Journal of Clinical Pathways
News
09/27/2022

Yvette C Terrie

Yvette C Terrie
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide...
09/27/2022
Journal of Clinical Pathways
News
09/22/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent study suggest that while Medicare eligibility and enrollment at age 65 led to increased utilization of some high-value and low-value care services, there were no changes in the utilization of most other services offered.
Findings from a recent study suggest that while Medicare eligibility and enrollment at age 65 led to increased utilization of some high-value and low-value care services, there were no changes in the utilization of most other services offered.
Findings from a recent study...
09/22/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement